Immix Biopharma Statistics
Total Valuation
Immix Biopharma has a market cap or net worth of $522.17 million. The enterprise value is $422.83 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, after market close.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immix Biopharma has 53.01 million shares outstanding. The number of shares has increased by 16.55% in one year.
| Current Share Class | 53.01M |
| Shares Outstanding | 53.01M |
| Shares Change (YoY) | +16.55% |
| Shares Change (QoQ) | +25.99% |
| Owned by Insiders (%) | 12.83% |
| Owned by Institutions (%) | 40.18% |
| Float | 36.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.56 |
| P/TBV Ratio | 5.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.01, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.01 |
| Quick Ratio | 9.93 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.00% and return on invested capital (ROIC) is -34.29%.
| Return on Equity (ROE) | -55.00% |
| Return on Assets (ROA) | -29.30% |
| Return on Invested Capital (ROIC) | -34.29% |
| Return on Capital Employed (ROCE) | -31.62% |
| Weighted Average Cost of Capital (WACC) | 5.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.40M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immix Biopharma has paid $37,724 in taxes.
| Income Tax | 37,724 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +476.02% in the last 52 weeks. The beta is 0.21, so Immix Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +476.02% |
| 50-Day Moving Average | 9.13 |
| 200-Day Moving Average | 5.06 |
| Relative Strength Index (RSI) | 54.03 |
| Average Volume (20 Days) | 713,023 |
Short Selling Information
The latest short interest is 3.12 million, so 5.88% of the outstanding shares have been sold short.
| Short Interest | 3.12M |
| Short Previous Month | 3.00M |
| Short % of Shares Out | 5.88% |
| Short % of Float | 8.54% |
| Short Ratio (days to cover) | 3.59 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.96M |
| Pretax Income | -29.40M |
| Net Income | -29.44M |
| EBITDA | -29.71M |
| EBIT | -29.96M |
| Earnings Per Share (EPS) | -$0.89 |
Full Income StatementBalance Sheet
The company has $100.41 million in cash and $1.07 million in debt, with a net cash position of $99.34 million or $1.87 per share.
| Cash & Cash Equivalents | 100.41M |
| Total Debt | 1.07M |
| Net Cash | 99.34M |
| Net Cash Per Share | $1.87 |
| Equity (Book Value) | 93.80M |
| Book Value Per Share | 1.77 |
| Working Capital | 91.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$23.93 million and capital expenditures -$732,925, giving a free cash flow of -$24.66 million.
| Operating Cash Flow | -23.93M |
| Capital Expenditures | -732,925 |
| Depreciation & Amortization | 245,747 |
| Net Borrowing | n/a |
| Free Cash Flow | -24.66M |
| FCF Per Share | -$0.47 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immix Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.55% |
| Shareholder Yield | -16.55% |
| Earnings Yield | -5.64% |
| FCF Yield | -4.72% |
Analyst Forecast
The average price target for Immix Biopharma is $19.20, which is 94.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.20 |
| Price Target Difference | 94.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
